themed boat tour – whose highlights include a visit to pine-shaded Kastani beach, where many key scenes were filmed, and a trip to the picturesque rock-top chapel of Agios Ioannis Kastri ...

Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety ...

Agios' ACTIVATE-Kids trial showed 31.6% of mitapivat-treated children met the hemoglobin response endpoint vs. 0% in the placebo group. Agios reported Q4 Pyrukynd revenue of $10.7M, exceeding the ...

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ story “gaining traction over the next 12 ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of $54.00. The company’s shares ...

Feb. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported ...

In this article, we are going to take a look at where Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...